Literature DB >> 19235589

Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole.

Mohammad Hossein Pourgholami1, Zhao Yan Cai, Lisa Wang, Samina Badar, Matthew Links, David Lawson Morris.   

Abstract

Vascular endothelial growth factor (VEGF) is the key molecule mediating tumor growth and malignant ascites formation. We recently reported that, in an end stage OVCAR-3 xenograft model, albendazole (ABZ) suppresses ascites formation, but not tumor growth. Hence, in the present study, we assessed the effect of ABZ on in vitro OVCAR-3 cell proliferation plus in vivo tumor growth, however, initiating ABZ treatment at mid stage (3 weeks post cell inoculation) rather than end stage disease. Here, ABZ treatment led to potent inhibition of cell proliferation, VEGF suppression, complete inhibition of ascites formation and most strikingly arrest of tumor growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235589     DOI: 10.1080/07357900802210752

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  9 in total

Review 1.  Role of the cytoskeleton in formation and maintenance of angiogenic sprouts.

Authors:  Kayla J Bayless; Greg A Johnson
Journal:  J Vasc Res       Date:  2011-04-04       Impact factor: 1.934

2.  Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.

Authors:  Mohammad H Pourgholami; Zhao Y Cai; Samina Badar; Kiran Wangoo; Marianne S Poruchynsky; David L Morris
Journal:  BMC Cancer       Date:  2010-04-15       Impact factor: 4.430

3.  Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Clin Exp Oncol       Date:  2013

4.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

5.  Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.

Authors:  Afshin Amini; Samar Masoumi Moghaddam; David L Morris; Mohammad H Pourgholami
Journal:  J Oncol       Date:  2011-09-26       Impact factor: 4.375

6.  Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.

Authors:  Lubna Noorani; Martina Stenzel; Roger Liang; Mohammad H Pourgholami; David L Morris
Journal:  J Nanobiotechnology       Date:  2015-03-25       Impact factor: 10.435

7.  Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Res Ther Oncol       Date:  2014-04-09

8.  Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis.

Authors:  Xuan Zhang; Jing Zhao; Xiangyang Gao; Dongsheng Pei; Chao Gao
Journal:  Exp Ther Med       Date:  2016-12-22       Impact factor: 2.447

9.  Solid Lipid Nanoparticles of Albendazole for Enhancing Cellular Uptake and Cytotoxicity against U-87 MG Glioma Cell Lines.

Authors:  Gregory Marslin; Karthik Siram; Xiang Liu; Vinoth Kumar Megraj Khandelwal; Shen Xiaolei; Wang Xiang; Gregory Franklin
Journal:  Molecules       Date:  2017-11-22       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.